{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:01:05Z","timestamp":1794574865499,"version":"4.9.1"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41582-026-01212-z","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:59:11Z","timestamp":1779202751000},"page":"457-471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rethinking prognosis in multiple sclerosis: a multiaxial perspective"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6267","authenticated-orcid":false,"given":"Luca","family":"Prosperini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Battistini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Bodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-2682","authenticated-orcid":false,"given":"Declan","family":"Chard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1367","authenticated-orcid":false,"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5509","authenticated-orcid":false,"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-8892","authenticated-orcid":false,"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Magliozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4320","authenticated-orcid":false,"given":"Maria Assunta","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Sastre-Garriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2504-6959","authenticated-orcid":false,"given":"Menno M.","family":"Schoonheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-104X","authenticated-orcid":false,"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Stankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-5359","authenticated-orcid":false,"given":"Mar","family":"Tintor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Yousry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-4067","authenticated-orcid":false,"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MAGNIMS network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Deluca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Granziera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Pareto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Toosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1212_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B. & Ciccarelli, O. Multiple sclerosis. Lancet 391, 1622\u20131636 (2018).","journal-title":"Lancet"},{"key":"1212_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","volume":"15","author":"D Rotstein","year":"2019","unstructured":"Rotstein, D. & Montalban, X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat. Rev. Neurol. 15, 287\u2013300 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","volume":"77","author":"K Bjornevik","year":"2020","unstructured":"Bjornevik, K. et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 77, 58\u201364 (2020).","journal-title":"JAMA Neurol."},{"key":"1212_CR4","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller, J. et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol. 80, 1232\u20131245 (2023).","journal-title":"JAMA Neurol."},{"key":"1212_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann, T. et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 22, 78\u201388 (2023).","journal-title":"Lancet Neurol."},{"key":"1212_CR6","doi-asserted-by":"publisher","first-page":"100977","DOI":"10.1016\/j.lanepe.2024.100977","volume":"44","author":"E Portaccio","year":"2024","unstructured":"Portaccio, E. et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg. Health Eur. 44, 100977 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1212_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00401-012-0953-0","volume":"123","author":"J Antel","year":"2012","unstructured":"Antel, J., Antel, S., Caramanos, Z., Arnold, D. L. & Kuhlmann, T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol. 123, 627\u2013638 (2012).","journal-title":"Acta Neuropathol."},{"key":"1212_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1212\/CPJ.0000000000001045","volume":"11","author":"TL Vollmer","year":"2021","unstructured":"Vollmer, T. L., Nair, K. V., Williams, I. M. & Alvarez, E. Multiple sclerosis phenotypes as a continuum: the role of neurologic reserve. Neurol. Clin. Pract. 11, 342\u2013351 (2021).","journal-title":"Neurol. Clin. Pract."},{"key":"1212_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41582-025-01115-5","volume":"21","author":"A van der Walt","year":"2025","unstructured":"van der Walt, A. et al. Advancing multiple sclerosis management in older adults. Nat. Rev. Neurol. 21, 432\u2013448 (2025).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/brain\/awh714","volume":"129","author":"C Confavreux","year":"2006","unstructured":"Confavreux, C. & Vukusic, S. Age at disability milestones in multiple sclerosis. Brain 129, 595\u2013605 (2006).","journal-title":"Brain"},{"key":"1212_CR11","doi-asserted-by":"publisher","first-page":"103144","DOI":"10.1016\/j.msard.2021.103144","volume":"54","author":"M Cohen","year":"2021","unstructured":"Cohen, M. et al. Should we still only rely on EDSS to evaluate disability in multiple sclerosis patients? A study of inter and intra rater reliability. Mult. Scler. Relat. Disord. 54, 103144 (2021).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1212_CR12","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","volume":"133","author":"A Scalfari","year":"2010","unstructured":"Scalfari, A. et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133, 1914\u20131929 (2010).","journal-title":"Brain"},{"key":"1212_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He, A. et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 19, 307\u2013316 (2020).","journal-title":"Lancet Neurol."},{"key":"1212_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1212\/WNL.0000000000006810","volume":"92","author":"C Gasperini","year":"2019","unstructured":"Gasperini, C. et al. Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology 92, 180\u2013192 (2019).","journal-title":"Neurology"},{"key":"1212_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman, A. M., Tapia-Maltos, M. A., Johnson, K., Greenwood, M. & Bielekova, B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front. Neurol. 8, 577 (2017).","journal-title":"Front. Neurol."},{"key":"1212_CR16","doi-asserted-by":"publisher","first-page":"854390","DOI":"10.3389\/fneur.2022.854390","volume":"13","author":"N Manouchehri","year":"2022","unstructured":"Manouchehri, N. et al. Efficacy of disease modifying therapies in progressive MS and how immune senescence may explain their failure. Front. Neurol. 13, 854390 (2022).","journal-title":"Front. Neurol."},{"key":"1212_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41583-018-0053-9","volume":"19","author":"M Di Filippo","year":"2018","unstructured":"Di Filippo, M., Portaccio, E., Mancini, A. & Calabresi, P. Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nat. Rev. Neurosci. 19, 599\u2013609 (2018).","journal-title":"Nat. Rev. Neurosci."},{"key":"1212_CR18","doi-asserted-by":"publisher","first-page":"103108","DOI":"10.1016\/j.nicl.2022.103108","volume":"35","author":"MM Schoonheim","year":"2022","unstructured":"Schoonheim, M. M., Broeders, T. A. A. & Geurts, J. J. G. The network collapse in multiple sclerosis: an overview of novel concepts to address disease dynamics. Neuroimage Clin. 35, 103108 (2022).","journal-title":"Neuroimage Clin."},{"key":"1212_CR19","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1093\/brain\/awad073","volume":"146","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay, C. et al. The radiologically isolated syndrome: revised diagnostic criteria. Brain 146, 3431\u20133443 (2023).","journal-title":"Brain"},{"key":"1212_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/14737175.2020.1746645","volume":"20","author":"FLA Yusuf","year":"2020","unstructured":"Yusuf, F. L. A. et al. A systematic review of morbidities suggestive of the multiple sclerosis prodrome. Expert Rev. Neurother. 20, 799\u2013819 (2020).","journal-title":"Expert Rev. Neurother."},{"key":"1212_CR21","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-023-12173-4","volume":"271","author":"KE Harding","year":"2024","unstructured":"Harding, K. E., Kreft, K. L., Ben-Shlomo, Y. & Robertson, N. P. Prodromal multiple sclerosis: considerations and future utility. J. Neurol. 271, 2129\u20132140 (2024).","journal-title":"J. Neurol."},{"key":"1212_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41582-022-00686-x","volume":"18","author":"RA Marrie","year":"2022","unstructured":"Marrie, R. A. et al. From the prodromal stage of multiple sclerosis to disease prevention. Nat. Rev. Neurol. 18, 559\u2013572 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","volume":"72","author":"DT Okuda","year":"2009","unstructured":"Okuda, D. T. et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72, 800\u2013805 (2009).","journal-title":"Neurology"},{"key":"1212_CR24","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1093\/brain\/awad185","volume":"146","author":"N De Stefano","year":"2023","unstructured":"De Stefano, N. & Rovira, \u00c0 Do we need new MRI criteria for the diagnosis of radiologically isolated syndrome? Brain 146, e102\u2013e103 (2023).","journal-title":"Brain"},{"key":"1212_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28271","volume":"4","author":"C Lebrun-Fr\u00e9nay","year":"2021","unstructured":"Lebrun-Fr\u00e9nay, C. et al. Risk factors and time to clinical symptoms of multiple sclerosis among patients with radiologically isolated syndrome. JAMA Netw. Open 4, e2128271 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1212_CR26","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1111\/ene.15922","volume":"30","author":"T Abou Mrad","year":"2023","unstructured":"Abou Mrad, T., Naja, K., Khoury, S. J. & Hannoun, S. Central vein sign and paramagnetic rim sign: from radiologically isolated syndrome to multiple sclerosis. Eur. J. Neurol. 30, 2912\u20132918 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR27","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/brain\/awy021","volume":"141","author":"C Matute-Blanch","year":"2018","unstructured":"Matute-Blanch, C. et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain 141, 1085\u20131093 (2018).","journal-title":"Brain"},{"key":"1212_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/13524585231219131","volume":"30","author":"R Schneider","year":"2024","unstructured":"Schneider, R. et al. Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome. Mult. Scler. 30, 156\u2013165 (2024).","journal-title":"Mult. Scler."},{"key":"1212_CR29","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2217\/epi-2020-0172","volume":"12","author":"M Mu\u00f1oz-San Mart\u00edn","year":"2020","unstructured":"Mu\u00f1oz-San Mart\u00edn, M. et al. Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers. Epigenomics 12, 2065\u20132076 (2020).","journal-title":"Epigenomics"},{"key":"1212_CR30","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1177\/1352458518815597","volume":"25","author":"A Filippatou","year":"2019","unstructured":"Filippatou, A. et al. Spinal cord and infratentorial lesions in radiologically isolated syndrome are associated with decreased retinal ganglion cell\/inner plexiform layer thickness. Mult. Scler. 25, 1878\u20131887 (2019).","journal-title":"Mult. Scler."},{"key":"1212_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68825-6","volume":"14","author":"M Rold\u00e1n","year":"2024","unstructured":"Rold\u00e1n, M. et al. Assessing the visual afferent pathway with the multifocal visual evoked potentials in the radiologically isolated syndrome. Sci. Rep. 14, 20169 (2024).","journal-title":"Sci. Rep."},{"key":"1212_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.26555","volume":"93","author":"DT Okuda","year":"2023","unstructured":"Okuda, D. T. et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann. Neurol. 93, 604\u2013614 (2023).","journal-title":"Ann. Neurol."},{"key":"1212_CR33","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2023.2815","volume":"80","author":"C Lebrun-Fr\u00e9nay","year":"2023","unstructured":"Lebrun-Fr\u00e9nay, C. et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial. JAMA Neurol. 80, 1080\u20131088 (2023).","journal-title":"JAMA Neurol."},{"key":"1212_CR34","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban, X. et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 24, 850\u2013865 (2025).","journal-title":"Lancet Neurol."},{"key":"1212_CR35","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1093\/brain\/awac220","volume":"145","author":"G Arrambide","year":"2022","unstructured":"Arrambide, G. et al. The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. Brain 145, 3931\u20133942 (2022).","journal-title":"Brain"},{"key":"1212_CR36","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.nicl.2022.103194","volume":"36","author":"H Kolb","year":"2022","unstructured":"Kolb, H. et al. From pathology to MRI and back: clinically relevant biomarkers of multiple sclerosis lesions. Neuroimage Clin. 36, 103194 (2022).","journal-title":"Neuroimage Clin."},{"key":"1212_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200253","volume":"11","author":"S Borrelli","year":"2024","unstructured":"Borrelli, S. et al. Central vein sign, cortical lesions, and paramagnetic rim lesions for the diagnostic and prognostic workup of multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 11, e200253 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamaneurol.2023.4737","volume":"81","author":"A Cagol","year":"2024","unstructured":"Cagol, A. et al. Diagnostic performance of cortical lesions and the central vein sign in multiple sclerosis. JAMA Neurol. 81, 143\u2013153 (2024).","journal-title":"JAMA Neurol."},{"key":"1212_CR39","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41582-025-01141-3","volume":"21","author":"M Moccia","year":"2025","unstructured":"Moccia, M., Ciccarelli, O. & Thompson, A. Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis. Nat. Rev. Neurol. 21, 664\u2013666 (2025).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR40","doi-asserted-by":"publisher","first-page":"100978","DOI":"10.1016\/j.lanepe.2024.100978","volume":"44","author":"MA Rocca","year":"2024","unstructured":"Rocca, M. A. et al. Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. Lancet Reg. Health Eur. 44, 100978 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1212_CR41","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1177\/1352458519856847","volume":"25","author":"R Brandstadter","year":"2019","unstructured":"Brandstadter, R., Katz Sand, I. & Sumowski, J. F. Beyond rehabilitation: a prevention model of reserve and brain maintenance in multiple sclerosis. Mult. Scler. 25, 1372\u20131378 (2019).","journal-title":"Mult. Scler."},{"key":"1212_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jnnp-2020-323087","volume":"92","author":"CM Allen","year":"2021","unstructured":"Allen, C. M., Mowry, E., Tintore, M. & Evangelou, N. Prognostication and contemporary management of clinically isolated syndrome. J. Neurol. Neurosurg. Psychiatry 92, 391\u2013397 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1212_CR43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jamaneurol.2013.599","volume":"70","author":"A Scalfari","year":"2013","unstructured":"Scalfari, A. et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol. 70, 214\u2013222 (2013).","journal-title":"JAMA Neurol."},{"key":"1212_CR44","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/jnnp-2023-331748","volume":"94","author":"W Dzau","year":"2023","unstructured":"Dzau, W. et al. Risk of secondary progressive multiple sclerosis after early worsening of disability. J. Neurol. Neurosurg. Psychiatry 94, 984\u2013991 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1212_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02555-7","volume":"13","author":"M Margoni","year":"2023","unstructured":"Margoni, M., Preziosa, P., Rocca, M. A. & Filippi, M. Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis. Transl. Psychiatry 13, 264 (2023).","journal-title":"Transl. Psychiatry"},{"key":"1212_CR46","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamaneurol.2020.4920","volume":"78","author":"E De Meo","year":"2021","unstructured":"De Meo, E. et al. Identifying the distinct cognitive phenotypes in multiple sclerosis. JAMA Neurol. 78, 414\u2013425 (2021).","journal-title":"JAMA Neurol."},{"key":"1212_CR47","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00415-023-12102-5","volume":"271","author":"D Mistri","year":"2024","unstructured":"Mistri, D. et al. Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment. J. Neurol. 271, 1571\u20131583 (2024).","journal-title":"J. Neurol."},{"key":"1212_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2005.11.025","volume":"243","author":"S Pittion-Vouyovitch","year":"2006","unstructured":"Pittion-Vouyovitch, S. et al. Fatigue in multiple sclerosis is related to disability, depression and quality of life. J. Neurol. Sci. 243, 39\u201345 (2006).","journal-title":"J. Neurol. Sci."},{"key":"1212_CR49","doi-asserted-by":"publisher","first-page":"6388","DOI":"10.1007\/s00415-024-12524-9","volume":"271","author":"J DeLuca","year":"2024","unstructured":"DeLuca, J. Fatigue in multiple sclerosis: can we measure it and can we treat it? J. Neurol. 271, 6388\u20136392 (2024).","journal-title":"J. Neurol."},{"key":"1212_CR50","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/brain\/awv105","volume":"138","author":"M Tintore","year":"2015","unstructured":"Tintore, M. et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138, 1863\u20131874 (2015).","journal-title":"Brain"},{"key":"1212_CR51","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/j.1468-1331.2007.01915.x","volume":"14","author":"JP Mostert","year":"2007","unstructured":"Mostert, J. P., De Groot, J. C., Ramsaransing, G. S. M., Koch, M. W. & De Keyser, J. Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. Eur. J. Neurol. 14, 1210\u20131215 (2007).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR52","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/brain\/awm329","volume":"131","author":"LK Fisniku","year":"2008","unstructured":"Fisniku, L. K. et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131, 808\u2013817 (2008).","journal-title":"Brain"},{"key":"1212_CR53","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1177\/1352458519877810","volume":"26","author":"M Tintore","year":"2020","unstructured":"Tintore, M. et al. The long-term outcomes of CIS patients in the Barcelona inception cohort: looking back to recognize aggressive MS. Mult. Scler. 26, 1658\u20131669 (2020).","journal-title":"Mult. Scler."},{"key":"1212_CR54","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/brain\/awab033","volume":"144","author":"L Haider","year":"2021","unstructured":"Haider, L. et al. Cortical involvement determines impairment 30 years after a clinically isolated syndrome. Brain 144, 1384\u20131395 (2021).","journal-title":"Brain"},{"key":"1212_CR55","doi-asserted-by":"publisher","first-page":"e1852","DOI":"10.1212\/WNL.0000000000008466","volume":"93","author":"MA Rocca","year":"2019","unstructured":"Rocca, M. A. et al. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. Neurology 93, e1852\u2013e1866 (2019).","journal-title":"Neurology"},{"key":"1212_CR56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41582-020-0314-x","volume":"16","author":"J Sastre-Garriga","year":"2020","unstructured":"Sastre-Garriga, J. et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat. Rev. Neurol. 16, 171\u2013182 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR57","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/1352458514564494","volume":"21","author":"N De Stefano","year":"2015","unstructured":"De Stefano, N. & Arnold, D. L. Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients. Mult. Scler. 21, 675\u2013676 (2015).","journal-title":"Mult. Scler."},{"key":"1212_CR58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaneurol.2020.4689","volume":"78","author":"M Filippi","year":"2021","unstructured":"Filippi, M. et al. Diagnosis of progressive multiple sclerosis from the imaging perspective: a review. JAMA Neurol. 78, 351\u2013364 (2021).","journal-title":"JAMA Neurol."},{"key":"1212_CR59","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","volume":"76","author":"M Absinta","year":"2019","unstructured":"Absinta, M. et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 76, 1474\u20131483 (2019).","journal-title":"JAMA Neurol."},{"key":"1212_CR60","doi-asserted-by":"publisher","first-page":"101009","DOI":"10.1016\/j.lanepe.2024.101009","volume":"44","author":"M Di Filippo","year":"2024","unstructured":"Di Filippo, M. et al. Fluid biomarkers in multiple sclerosis: from current to future applications. Lancet Reg. Health Eur. 44, 101009 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1212_CR61","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1177\/1352458520981910","volume":"27","author":"R Capuano","year":"2021","unstructured":"Capuano, R. et al. Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Mult. Scler. 27, 1706\u20131716 (2021).","journal-title":"Mult. Scler."},{"key":"1212_CR62","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001164","volume":"9","author":"S Floro","year":"2022","unstructured":"Floro, S. et al. Role of chitinase 3\u2013like 1 as a biomarker in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 9, e1164 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR63","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200050","volume":"10","author":"N Fissolo","year":"2023","unstructured":"Fissolo, N. et al. Serum levels of CXCL13 are associated with teriflunomide response in patients with multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 10, e200050 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR64","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200135","volume":"10","author":"K Lundblad","year":"2023","unstructured":"Lundblad, K. et al. CSF concentrations of CXCL13 and sCD27 before and after autologous hematopoietic stem cell transplantation for multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 10, e200135 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR65","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto, G. et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857\u2013870 (2017).","journal-title":"Ann. Neurol."},{"key":"1212_CR66","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR67","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1352458509359725","volume":"16","author":"J Salzer","year":"2010","unstructured":"Salzer, J., Svenningsson, A. & Sundstr\u00f6m, P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult. Scler. 16, 287\u2013292 (2010).","journal-title":"Mult. Scler."},{"key":"1212_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ana.22247","volume":"69","author":"M Gunnarsson","year":"2011","unstructured":"Gunnarsson, M. et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann. Neurol. 69, 83\u201389 (2011).","journal-title":"Ann. Neurol."},{"key":"1212_CR69","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle, J. et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92, e1007\u2013e1015 (2019).","journal-title":"Neurology"},{"key":"1212_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil, M. et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat. Commun. 11, 812 (2020).","journal-title":"Nat. Commun."},{"key":"1212_CR71","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 21, 246\u2013257 (2022).","journal-title":"Lancet Neurol."},{"key":"1212_CR72","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200052","volume":"10","author":"C Barro","year":"2023","unstructured":"Barro, C. et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 10, e200052 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR73","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier, S. et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 80, 287\u2013297 (2023).","journal-title":"JAMA Neurol."},{"key":"1212_CR74","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ana.25691","volume":"87","author":"E Oldoni","year":"2020","unstructured":"Oldoni, E. et al. CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity. Ann. Neurol. 87, 633\u2013645 (2020).","journal-title":"Ann. Neurol."},{"key":"1212_CR75","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ene.14100","volume":"27","author":"L Crno\u0161ija","year":"2020","unstructured":"Crno\u0161ija, L. et al. Evoked potentials can predict future disability in people with clinically isolated syndrome. Eur. J. Neurol. 27, 437\u2013444 (2020).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR76","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200416","volume":"12","author":"NK El Ayoubi","year":"2025","unstructured":"El Ayoubi, N. K. et al. Retinal optical coherence tomography longitudinal measures as prognostic biomarkers in multiple sclerosis: systematic review and meta-analysis. Neurol. Neuroimmunol. Neuroinflamm. 12, e200416 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR77","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1177\/1352458517707265","volume":"23","author":"M Hardmeier","year":"2017","unstructured":"Hardmeier, M., Leocani, L. & Fuhr, P. A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. Mult. Scler. 23, 1309\u20131319 (2017).","journal-title":"Mult. Scler."},{"key":"1212_CR78","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1474-4422(16)00068-5","volume":"15","author":"EH Martinez-Lapiscina","year":"2016","unstructured":"Martinez-Lapiscina, E. H. et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 15, 574\u2013584 (2016).","journal-title":"Lancet Neurol."},{"key":"1212_CR79","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/ene.15718","volume":"30","author":"G Bsteh","year":"2023","unstructured":"Bsteh, G. et al. Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis. Eur. J. Neurol. 30, 1025\u20131034 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR80","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/EB.S469182","volume":"16","author":"CD Guantay","year":"2024","unstructured":"Guantay, C. D. et al. Correlations between disability score, optical coherence tomography and microperimetry in patients with multiple sclerosis. Eye Brain 16, 89\u2013100 (2024).","journal-title":"Eye Brain"},{"key":"1212_CR81","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ana.24487","volume":"78","author":"S Saidha","year":"2015","unstructured":"Saidha, S. et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: a four\u2010year study. Ann. Neurol. 78, 801\u2013813 (2015).","journal-title":"Ann. Neurol."},{"key":"1212_CR82","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000279","volume":"3","author":"SC Krieger","year":"2016","unstructured":"Krieger, S. C., Cook, K., De Nino, S. & Fletcher, M. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol. Neuroimmunol. Neuroinflamm. 3, e279 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR83","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1352458517697830","volume":"24","author":"G Arrambide","year":"2018","unstructured":"Arrambide, G. et al. Spinal cord lesions: a modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult. Scler. 24, 301\u2013312 (2018).","journal-title":"Mult. Scler."},{"key":"1212_CR84","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/ana.25637","volume":"87","author":"KK Chung","year":"2020","unstructured":"Chung, K. K. et al. A 30-year clinical and magnetic resonance imaging observational study of multiple sclerosis and clinically isolated syndromes. Ann. Neurol. 87, 63\u201374 (2020).","journal-title":"Ann. Neurol."},{"key":"1212_CR85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/jnnp-2023-331799","volume":"95","author":"M Lauerer","year":"2023","unstructured":"Lauerer, M. et al. Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 95, 37\u201343 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1212_CR86","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s00415-023-11829-5","volume":"270","author":"S Ruggieri","year":"2023","unstructured":"Ruggieri, S. et al. The added value of spinal cord lesions to disability accrual in multiple sclerosis. J. Neurol. 270, 4995\u20135003 (2023).","journal-title":"J. Neurol."},{"key":"1212_CR87","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jnnp-2022-329854","volume":"94","author":"MA Rocca","year":"2023","unstructured":"Rocca, M. A. et al. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study. J. Neurol. Neurosurg. Psychiatry 94, 10\u201318 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1212_CR88","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.msard.2016.05.012","volume":"8","author":"S Galassi","year":"2016","unstructured":"Galassi, S. et al. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with interferon beta. Mult. Scler. Relat. Disord. 8, 99\u2013106 (2016).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1212_CR89","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/ana.25145","volume":"83","author":"A Eshaghi","year":"2018","unstructured":"Eshaghi, A. et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann. Neurol. 83, 210\u2013222 (2018).","journal-title":"Ann. Neurol."},{"key":"1212_CR90","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.25150","volume":"83","author":"CJ Azevedo","year":"2018","unstructured":"Azevedo, C. J. et al. Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease. Ann. Neurol. 83, 223\u2013234 (2018).","journal-title":"Ann. Neurol."},{"key":"1212_CR91","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/ene.14214","volume":"27","author":"M Petracca","year":"2020","unstructured":"Petracca, M. et al. Streamline density and lesion volume reveal a postero-anterior gradient of corpus callosum damage in multiple sclerosis. Eur. J. Neurol. 27, 1076\u20131082 (2020).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR92","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.25197","volume":"83","author":"R Magliozzi","year":"2018","unstructured":"Magliozzi, R. et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann. Neurol. 83, 739\u2013755 (2018).","journal-title":"Ann. Neurol."},{"key":"1212_CR93","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3389\/fneur.2020.00608","volume":"11","author":"A Huss","year":"2020","unstructured":"Huss, A. et al. A score based on NfL and glial markers may differentiate between relapsing-remitting and progressive MS course. Front. Neurol. 11, 608 (2020).","journal-title":"Front. Neurol."},{"key":"1212_CR94","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1177\/1352458514525867","volume":"20","author":"R Schlaeger","year":"2014","unstructured":"Schlaeger, R. et al. Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years. Mult. Scler. 20, 1348\u20131354 (2014).","journal-title":"Mult. Scler."},{"key":"1212_CR95","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200092","volume":"10","author":"FC Oertel","year":"2023","unstructured":"Oertel, F. C. et al. Visually evoked potential as prognostic biomarker for neuroaxonal damage in multiple sclerosis from a multicenter longitudinal cohort. Neurol. Neuroimmunol. Neuroinflamm. 10, e200092 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR96","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1600-0404.1984.tb00808.x","volume":"70","author":"M Hutchinson","year":"1984","unstructured":"Hutchinson, M., Blandford, S., Glynn, D. & Martin, E. A. Clinical correlates of abnormal brain-stem auditory evoked responses in multiple sclerosis. Acta Neurol. Scand. 70, 90\u201395 (1984).","journal-title":"Acta Neurol. Scand."},{"key":"1212_CR97","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/jcm14010141","volume":"14","author":"R Ciurleo","year":"2024","unstructured":"Ciurleo, R., De Salvo, S., Caminiti, F., Militi, A. & Bonanno, L. Olfactory evoked potentials and brain MRI outcomes in multiple sclerosis patients: a cross-sectional study. J. Clin. Med. 14, 141 (2024).","journal-title":"J. Clin. Med."},{"key":"1212_CR98","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1474-4422(17)30278-8","volume":"16","author":"A Petzold","year":"2017","unstructured":"Petzold, A. et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 16, 797\u2013812 (2017).","journal-title":"Lancet Neurol."},{"key":"1212_CR99","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/1352458520963926","volume":"27","author":"L Castelli","year":"2021","unstructured":"Castelli, L., Quartuccio, M. E., Ruggieri, S., De Giglio, L. & Prosperini, L. \u2018Posture second\u2019 strategy predicts disability progression in multiple sclerosis. Mult. Scler. 27, 1140\u20131144 (2021).","journal-title":"Mult. Scler."},{"key":"1212_CR100","doi-asserted-by":"publisher","first-page":"103802","DOI":"10.1016\/j.msard.2022.103802","volume":"63","author":"B Z\u00f6rner","year":"2022","unstructured":"Z\u00f6rner, B. et al. Prognosis of walking function in multiple sclerosis supported by gait pattern analysis. Mult. Scler. Relat. Disord. 63, 103802 (2022).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1212_CR101","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/brain\/awp032","volume":"132","author":"KM Zackowski","year":"2009","unstructured":"Zackowski, K. M. et al. Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 132, 1200\u20131209 (2009).","journal-title":"Brain"},{"key":"1212_CR102","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1148\/radiol.13121695","volume":"268","author":"L Prosperini","year":"2013","unstructured":"Prosperini, L. et al. Multiple sclerosis: white and gray matter damage associated with balance deficit detected at static posturography. Radiology 268, 181\u2013189 (2013).","journal-title":"Radiology"},{"key":"1212_CR103","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neurobiolaging.2019.03.022","volume":"83","author":"Y Stern","year":"2019","unstructured":"Stern, Y., Barnes, C. A., Grady, C., Jones, R. N. & Raz, N. Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience. Neurobiol. Aging 83, 124\u2013129 (2019).","journal-title":"Neurobiol. Aging"},{"key":"1212_CR104","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","volume":"15","author":"CB Vaughn","year":"2019","unstructured":"Vaughn, C. B. et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat. Rev. Neurol. 15, 329\u2013342 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR105","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.msard.2020.102724","volume":"49","author":"S Lynch","year":"2021","unstructured":"Lynch, S. et al. Disability measurement in multiple sclerosis patients 55 years and older: what is the Expanded Disability Status Scale really telling clinicians? Mult. Scler. Relat. Disord. 49, 102724 (2021).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1212_CR106","doi-asserted-by":"publisher","first-page":"1380025","DOI":"10.3389\/fimmu.2024.1380025","volume":"15","author":"S Samadzadeh","year":"2024","unstructured":"Samadzadeh, S. et al. Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT). Front. Immunol. 15, 1380025 (2024).","journal-title":"Front. Immunol."},{"key":"1212_CR107","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/jnnp-2024-335710","volume":"96","author":"A Salter","year":"2025","unstructured":"Salter, A., Lancia, S., Kowalec, K., Fitzgerald, K. & Marrie, R. A. Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 96, 1070\u20131076 (2025).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1212_CR108","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","volume":"13","author":"RA Marrie","year":"2017","unstructured":"Marrie, R. A. Comorbidity in multiple sclerosis: implications for patient care. Nat. Rev. Neurol. 13, 375\u2013382 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR109","doi-asserted-by":"publisher","first-page":"105943","DOI":"10.1016\/j.msard.2024.105943","volume":"92","author":"HA Frank","year":"2024","unstructured":"Frank, H. A. et al. Comorbidities and their association with outcomes in the multiple sclerosis population: a rapid review. Mult. Scler. Relat. Disord. 92, 105943 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1212_CR110","doi-asserted-by":"publisher","first-page":"106386","DOI":"10.1016\/j.msard.2025.106386","volume":"97","author":"C Atiyeh","year":"2025","unstructured":"Atiyeh, C. et al. Medication use is associated with cognitive deficits in people with multiple sclerosis. Mult. Scler. Relat. Disord. 97, 106386 (2025).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1212_CR111","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/ene.13904","volume":"26","author":"I Dekker","year":"2019","unstructured":"Dekker, I. et al. Predicting clinical progression in multiple sclerosis after 6 and 12 years. Eur. J. Neurol. 26, 893\u2013902 (2019).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR112","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1212\/WNL.0000000000002702","volume":"86","author":"JF Sumowski","year":"2016","unstructured":"Sumowski, J. F. et al. Brain reserve against physical disability progression over 5 years in multiple sclerosis. Neurology 86, 2006\u20132009 (2016).","journal-title":"Neurology"},{"key":"1212_CR113","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1212\/WNL.0b013e318296e98b","volume":"80","author":"JF Sumowski","year":"2013","unstructured":"Sumowski, J. F. et al. Brain reserve and cognitive reserve in multiple sclerosis: what you\u2019ve got and how you use it. Neurology 80, 2186\u20132193 (2013).","journal-title":"Neurology"},{"key":"1212_CR114","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1212\/WNL.0000000000000433","volume":"82","author":"JF Sumowski","year":"2014","unstructured":"Sumowski, J. F. et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology 82, 1776\u20131783 (2014).","journal-title":"Neurology"},{"key":"1212_CR115","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1177\/1352458506073511","volume":"13","author":"F Patti","year":"2007","unstructured":"Patti, F. et al. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Mult. Scler. J. 13, 783\u2013791 (2007).","journal-title":"Mult. Scler. J."},{"key":"1212_CR116","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1352458516646863","volume":"23","author":"K Bj\u00f8rnevik","year":"2017","unstructured":"Bj\u00f8rnevik, K. et al. Level of education and multiple sclerosis risk over a 50-year period: registry-based sibling study. Mult. Scler. J. 23, 213\u2013219 (2017).","journal-title":"Mult. Scler. J."},{"key":"1212_CR117","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/13524585241289276","volume":"31","author":"M Lefort","year":"2025","unstructured":"Lefort, M. et al. Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France. Mult. Scler. 31, 69\u201380 (2025).","journal-title":"Mult. Scler."},{"key":"1212_CR118","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41582-022-00735-5","volume":"18","author":"R Dobson","year":"2022","unstructured":"Dobson, R. et al. Social determinants of health in multiple sclerosis. Nat. Rev. Neurol. 18, 723\u2013734 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR119","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/brain\/awab385","volume":"145","author":"J Rodgers","year":"2022","unstructured":"Rodgers, J. et al. The impact of smoking cessation on multiple sclerosis disease progression. Brain 145, 1368\u20131378 (2022).","journal-title":"Brain"},{"key":"1212_CR120","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ana.27112","volume":"97","author":"F Alzamanan","year":"2024","unstructured":"Alzamanan, F., Ding, Y. & Harroud, A. Obesity and multiple sclerosis severity: a Mendelian randomization study. Ann. Neurol. 97, 90\u201394 (2024).","journal-title":"Ann. Neurol."},{"key":"1212_CR121","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2012.08.033","volume":"323","author":"RW Motl","year":"2012","unstructured":"Motl, R. W., Dlugonski, D., Pilutti, L., Sandroff, B. & McAuley, E. Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 323, 123\u2013127 (2012).","journal-title":"J. Neurol. Sci."},{"key":"1212_CR122","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1136\/jnnp-2022-330613","volume":"94","author":"J Sastre-Garriga","year":"2023","unstructured":"Sastre-Garriga, J. et al. Spinal cord reserve in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 94, 502\u2013510 (2023).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1212_CR123","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1177\/13524585241272046","volume":"30","author":"M Petracca","year":"2024","unstructured":"Petracca, M. et al. Brain reserve and timing of clinical onset in multiple sclerosis. Mult. Scler. 30, 1290\u20131295 (2024).","journal-title":"Mult. Scler."},{"key":"1212_CR124","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2024-000670","volume":"6","author":"N John","year":"2024","unstructured":"John, N. et al. Brain reserve and physical disability in secondary progressive multiple sclerosis. BMJ Neurol. Open 6, e000670 (2024).","journal-title":"BMJ Neurol. Open"},{"key":"1212_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/jon.70089","volume":"35","author":"J Lambe","year":"2025","unstructured":"Lambe, J., Thompson, N. R., Li, Y., Nakamura, K. & Ontaneda, D. Association of spinal cord radiomic features and disability in multiple sclerosis. J. Neuroimaging 35, e70089 (2025).","journal-title":"J. Neuroimaging"},{"key":"1212_CR126","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210136","volume":"104","author":"N Mongay-Ochoa","year":"2025","unstructured":"Mongay-Ochoa, N. et al. Association of the cervical canal area with disability and progression in people with multiple sclerosis. Neurology 104, e210136 (2025).","journal-title":"Neurology"},{"key":"1212_CR127","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1177\/13524585251372440","volume":"31","author":"E Barbuti","year":"2025","unstructured":"Barbuti, E. et al. How premorbid structural reserve affects disability accrual in multiple sclerosis. Mult. Scler. 31, 1472\u20131482 (2025).","journal-title":"Mult. Scler."},{"key":"1212_CR128","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214527","volume":"106","author":"L Bos","year":"2026","unstructured":"Bos, L. et al. Association of brain age with physical disability and cognitive impairment in people with multiple sclerosis of the same age. Neurology 106, e214527 (2026).","journal-title":"Neurology"},{"key":"1212_CR129","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200459","volume":"12","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Unraveling microstructural and macrostructural brain age dynamics in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 12, e200459 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR130","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(10)70094-6","volume":"9","author":"SV Ramagopalan","year":"2010","unstructured":"Ramagopalan, S. V., Dobson, R., Meier, U. C. & Giovannoni, G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 9, 727\u2013739 (2010).","journal-title":"Lancet Neurol."},{"key":"1212_CR131","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40120-017-0086-4","volume":"7","author":"MB Sintzel","year":"2018","unstructured":"Sintzel, M. B., Rametta, M. & Reder, A. T. Vitamin D and multiple sclerosis: a comprehensive review. Neurol. Ther. 7, 59\u201385 (2018).","journal-title":"Neurol. Ther."},{"key":"1212_CR132","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/jama.2025.1604","volume":"333","author":"E Thouvenot","year":"2025","unstructured":"Thouvenot, E. et al. High-dose vitamin d in clinically isolated syndrome typical of multiple sclerosis: the D-Lay MS randomized clinical trial. JAMA 333, 1413\u20131422 (2025).","journal-title":"JAMA"},{"key":"1212_CR133","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-019-0903-2","volume":"566","author":"S J\u00e4kel","year":"2019","unstructured":"J\u00e4kel, S. et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 566, 543\u2013547 (2019).","journal-title":"Nature"},{"key":"1212_CR134","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","volume":"619","author":"International Multiple Sclerosis Genetics Consortium & Multiple MS Consortium.","year":"2023","unstructured":"International Multiple Sclerosis Genetics Consortium & Multiple MS Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature 619, 323\u2013331 (2023).","journal-title":"Nature"},{"key":"1212_CR135","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ana.26807","volume":"94","author":"C Gasperi","year":"2023","unstructured":"Gasperi, C. et al. A genetic risk variant for multiple sclerosis severity is associated with brain atrophy. Ann. Neurol. 94, 1080\u20131085 (2023).","journal-title":"Ann. Neurol."},{"key":"1212_CR136","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/ana.27144","volume":"97","author":"M Protopapa","year":"2025","unstructured":"Protopapa, M. et al. Increased disability progression in rs10191329AA carriers with multiple sclerosis is preceded by neurofilament light chain elevations. Ann. Neurol. 97, 596\u2013605 (2025).","journal-title":"Ann. Neurol."},{"key":"1212_CR137","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1177\/1352458518799629","volume":"24","author":"L Lavorgna","year":"2018","unstructured":"Lavorgna, L. et al. e-Health and multiple sclerosis: an update. Mult. Scler. 24, 1657\u20131664 (2018).","journal-title":"Mult. Scler."},{"key":"1212_CR138","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0570","volume":"2","author":"VJ Block","year":"2019","unstructured":"Block, V. J. et al. Association of continuous assessment of step count by remote monitoring with disability progression among adults with multiple sclerosis. JAMA Netw. Open 2, e190570 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1212_CR139","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","volume":"19","author":"RHB Benedict","year":"2020","unstructured":"Benedict, R. H. B., Amato, M. P., DeLuca, J. & Geurts, J. J. G. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 19, 860\u2013871 (2020).","journal-title":"Lancet Neurol."},{"key":"1212_CR140","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/1352458511431076","volume":"18","author":"D Langdon","year":"2012","unstructured":"Langdon, D. et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult. Scler. 18, 891\u2013898 (2012).","journal-title":"Mult. Scler."},{"key":"1212_CR141","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/neurosci3040048","volume":"3","author":"E Portaccio","year":"2022","unstructured":"Portaccio, E. & Amato, M. P. Cognitive impairment in multiple sclerosis: an update on assessment and management. NeuroSci 3, 667\u2013676 (2022).","journal-title":"NeuroSci"},{"key":"1212_CR142","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/13524585241230184","volume":"30","author":"PT Waskowiak","year":"2024","unstructured":"Waskowiak, P. T., Ruitenberg, M. F. & Hulst, H. E. Neuropsychological assessment in MS is outdated and is in need for innovation: yes. Mult. Scler. 30, 150\u2013151 (2024).","journal-title":"Mult. Scler."},{"key":"1212_CR143","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","volume":"11","author":"MP Wattjes","year":"2015","unstructured":"Wattjes, M. P. et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat. Rev. Neurol. 11, 597\u2013606 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"1212_CR144","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40120-024-00670-1","volume":"14","author":"LG Ree\u00df","year":"2025","unstructured":"Ree\u00df, L. G., Salih, H., Delikaya, M., Paul, F. & Oertel, F. C. Barriers in healthcare to the use of optical coherence tomography angiography in multiple sclerosis. Neurol. Ther. 14, 45\u201356 (2025).","journal-title":"Neurol. Ther."},{"key":"1212_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2013.12.045","volume":"125","author":"\u0160t\u011btk\u00e1\u0159ov\u00e1, I. 7","year":"2014","unstructured":"\u0160t\u011btk\u00e1\u0159ov\u00e1, I. 7 Evoked potentials in diagnosis and prognosis of multiple sclerosis. Clin. Neurophysiol. 125, e27 (2014).","journal-title":"Clin. Neurophysiol."},{"key":"1212_CR146","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-018-0408-5","volume":"10","author":"AC van Loenhoud","year":"2018","unstructured":"van Loenhoud, A. C., Groot, C., Vogel, J. W., van der Flier, W. M. & Ossenkoppele, R. Is intracranial volume a suitable proxy for brain reserve? Alzheimers Res. Ther. 10, 91 (2018).","journal-title":"Alzheimers Res. Ther."},{"key":"1212_CR147","doi-asserted-by":"publisher","first-page":"737384","DOI":"10.3389\/fresc.2021.737384","volume":"2","author":"G Lavelle","year":"2022","unstructured":"Lavelle, G. et al. Validity and acceptability of wearable devices for monitoring step-count and activity minutes among people with multiple sclerosis. Front. Rehabil. Sci. 2, 737384 (2022).","journal-title":"Front. Rehabil. Sci."},{"key":"1212_CR148","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001051","volume":"8","author":"T-Y Lin","year":"2021","unstructured":"Lin, T.-Y. et al. Increased serum neurofilament light and thin ganglion cell-inner plexiform layer are additive risk factors for disease activity in early multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 8, e1051 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1212_CR149","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/ene.12696","volume":"22","author":"R Bergamaschi","year":"2015","unstructured":"Bergamaschi, R. et al. BREMSO: a simple score to predict early the natural course of multiple sclerosis. Eur. J. Neurol. 22, 981\u2013989 (2015).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR150","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1111\/ene.14845","volume":"28","author":"C Gasperini","year":"2021","unstructured":"Gasperini, C. et al. Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. Eur. J. Neurol. 28, 2533\u20132542 (2021).","journal-title":"Eur. J. Neurol."},{"key":"1212_CR151","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/jnnp-2018-318802","volume":"90","author":"EC Tallantyre","year":"2019","unstructured":"Tallantyre, E. C. et al. How common is truly benign MS in a UK population? J. Neurol. Neurosurg. Psychiatry 90, 522\u2013528 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01212-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01212-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01212-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:04:05Z","timestamp":1782993845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01212-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":151,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01212-z","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"13 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.P. declares personal fees and non-financial support from Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi and Viatris. C.T. declares honoraria for speaking and travel grants from Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi and Teva. F.B. has served on the steering committee or data safety monitoring board (DSMB) for Biogen, Merck, ATRI\/ACTC and Prothena; declares consultancy fees from Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Janssen and Combinostics; has research agreements with Merck, Biogen, GE Healthcare and Roche; is a co-founder and shareholder of Queen Square Analytics; and is supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at University College London Hospitals (UCLH). L.B. declares personal compensation for consultancy, research grants and support for attendance at conferences from Bristol Myers Squibb, Merck, Novartis, Roche Sanofi, Janssen, Horizon and GlaxoSmithKline. B.B. declares funding for travel and speaker honoraria from Novartis, Sanofi, Roche and Merck and research support from Biogen. M.C. declares speaker honoraria from Biogen, Bristol Myers Squibb, Celgene, Merck, Novartis, Roche and Sanofi and research support from the Progressive MS Alliance and Italian Minister of Health. D.C. declares consultancy fees from Biogen and Roche; research funding from Roche, the International Progressive Multiple Sclerosis Alliance, the Medical Research Council, the Multiple Sclerosis Society and the NIHR UCLH Biomedical Research Centre; and speaker honoraria from Novartis. O.C. is a member of the independent DSMB for Novartis and the advisory board for Biogen; declares research grant support from the MS Society of Great Britain and Northern Ireland, the NIHR UCLH Biomedical Research Centre, the Rosetrees Trust, the National MS Society and the NIHR Health Technology Assessment Programme; and declares honoraria as Deputy Editor of\n                      Neurology\n                      . C.E. declares personal compensation for consulting or speaking from Biogen, Bristol Myers Squibb, Merck, Novartis, Roche and Sanofi. M.F. is Editor-in-Chief of the\n                      Journal of Neurology\n                      and Associate Editor of\n                      Human Brain Mapping\n                      ,\n                      Neurological Sciences\n                      and\n                      Radiology\n                      ; declares compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche and Sanofi; has undertaken speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda and Teva; has participated in advisory boards for Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi and Takeda; has undertaken scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol Myers Squibb, Eli Lilly, Novartis and Sanofi; and declares research support from Biogen, Merck, Novartis, Roche, the Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla and ARiSLA (Fondazione Italiana di Ricerca per la SLA). L.K. declares steering committee, advisory board and consultancy fees from AbbVie, Actelion, Auriga Vision AG, Biogen, Celgene, Desitin, Eli Lilly, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, Janssen, Japan Tobacco, Merck, Minoryx, Novartis, Roche, Sanofi, Santhera, Senda, Shionogi, Teva and Wellmera; speaker fees from Celgene, Janssen, Merck, Novartis and Roche; support for educational activities from Biogen, Desitin, Novartis, Sanofi and Teva; license fees for Neurostatus products; and grants from the European Union, Innosuisse, Novartis, Roche Research Foundation, the Swiss MS Society and the Swiss National Research Foundation to his institution (University Hospital Basel\/Foundation Clinical Neuroimmunology and Neuroscience Basel). J.K. declares speaker fees, research support, travel support and\/or compensation for advisory boards from the Swiss MS Society, the Swiss National Research Foundation (grant no. 320030_212534\/1), the University of Basel, the Progressive MS Alliance, Alnylam, Bayer, Biogen, Bristol Myers Squibb, Celgene, Immunic, Merck, Neurogenesis, Novartis, Octave Bioscience, Quanterix, Roche, Sanofi and Stata DX. M.A.R. declares consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen and Roche; speaker honoraria from AstraZeneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva; and research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research and Fondazione Italiana Sclerosi Multipla and is Associate Editor for\n                      Multiple Sclerosis and Related Disorders\n                      . A.R. declares fees for scientific advisory boards from Novartis, Sanofi Genzyme, Synthetic MR, TensorMedical, Roche, Biogen and OLEA Medical; speaker honoraria from Bayer, Sanofi Genzyme, Merck Serono, Teva Pharmaceutical Industries, Novartis, Roche, Bristol Myers Squibb and Biogen; and research support from Fondo de Investigaci\u00f3n en Salud (grant no. PI19\/00950) from Instituto de Salud Carlos III, Spain. S.R. declares personal fees and non-financial support from Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis and Roche. J.S.-G. declares fees from Sanofi, Biogen, Celgene, Merck, Biopass, Novartis and Roche and research support from Fondo de Investigaci\u00f3n en Salud (grant no. PI19\/00950) from Instituto de Salud Carlos III, Spain. M.M.S. is a member of the editorial boards of\n                      Neurology\n                      and\n                      Frontiers in Neurology\n                      ; declares research support from the Dutch Sanofi Genzyme, Merck Serono MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW; and consultancy for or research support from Atara Biotherapeutics, Biogen, Celgene\/Bristol Myers Squibb, Genzyme, MedDay and Merck. M.P.S. declares consulting fees from Biogen, Novartis, Roche, Sanofi, Merck, Alexion, Bristol Myers Squibb and Immunic. B.S. declares lecturing fees from Biogen Idec, Merck Serono, Novartis, Sanofi and Janssen and unconditional research support (to the institution) from Merck Serono, Novartis and Roche. M.T. declares compensation for consulting services, speaking honoraria and research support from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Immunic Therapeutics, Janssen, Merck Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio and Teva Pharmaceuticals; DSMB for Parexel and UCB Biopharma; and Relapse Adjudication Committee for IMCYSE SA. T.Y. declares personal fees from Biogen, Novartis, Bayer HealthCare Pharmaceuticals and Hikma and research support from Biogen, GlaxoSmithKline, Novartis and Schering. X.M. declares speaking honoraria and travel expenses for participation in scientific meetings, membership of steering committee member of clinical trials or participation in advisory boards of clinical trials with AbbVie, Actelion, Alexion, Biogen, Bristol Myers Squibb\/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic Therapeutics, Janssen Pharmaceuticals, MedDay, Merck, Mylan, NervGen, Novartis, Sandoz, Sanofi Genzyme, Teva Pharmaceutical, TG15 Therapeutics, Excemed, MSIF and NMSS. C.\u00a0Gasparini declares honoraria for speaking and travel grants from Biogen, Merck, Novartis, Roche, Sanofi, Teva and Viatris. N.D.S. and R.M. declare no competing interests.\u00a0G.D.\u00a0declares personal compensation for serving as a consultant for Neurology Academy and on speakers bureaus for Merck, Roche, and Novartis; his institution has received research support from the National Institute for Health and Care Research, Biomedical Research Center BRC (Oxford); National Health and Medical Research (Australia); UK MS Society; the Oxford-Quinnipiac Partnership; the US Department of Defense; Wellcome Institutional Strategic Support Fund (Oxford); Bristol Myers Squibb; University of Oxford (John Fell Fund); and National Health and Medical Research (Australia); and has non-compensated relationships that are relevant to American Academy of Neurology (AAN) interests or activities as an editorial board member with\n                      Multiple Sclerosis\n                      \u00a0journal; as a vice-chair of grant review panel with the UK MS Society; as a steering group member with MS Academy; and as a board of directors member of SEQUINS.\u00a0C.\u00a0Granziera declares contracts or grants paid to her institution (University Hospital Basel and Research Center for Clinical Neuroimmunology and Neuroscience, Basel) from Sanofi Genzyme, Hoffmann La Roche, Novartis, and Biogen; payment or honoraria for lectures, presentations, and educational events to their institution from Sanofi Genzyme, Hoffmann La Roche, Novartis, Biogen, and Merck.\u00a0D.P. declares research support from Fondo de Investigaciones Sanitarias (PI18\/00823, PI22\/01709), cofounded by the European Union.\u00a0A.T.\u00a0declares speaker honoraria from Merck, Biomedia, Sereno Symposia International Foundation, Bayer and At the Limits and meeting expenses from Merck, Biogen Idec and Novartis. He was the UK PI for two clinical trials sponsored by MEDDAY pharmaceutical company (MD1003 in optic neuropathy (MS\u2010ON\u2010NCT02220244) and progressive MS (MS\u2010SPI2\u2010NCT02936037)). He has been supported by recent grants from the MRC (MR\/S026088\/1), NIHR BRC (541\/CAP\/OC\/818837) and RoseTrees Trust (A1332 and PGL21\/10079). He is an associate editor for\n                      Frontiers in Neurology\n                      \u2014 Neuro\u2010ophthalmology section and on the editorial board for\n                      Neurology and Multiple Sclerosis\n                      \u00a0journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}